成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 17933-03-8 Chemical Structure| 17933-03-8

Structure of 3-Tolylboronic acid
CAS No.: 17933-03-8

Chemical Structure| 17933-03-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 17933-03-8

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Yuan, Gengyang ; Dhaynaut, Maeva ; Lan, Yu ; Guehl, Nicolas J. ; Huynh, Dalena ; Iyengar, Suhasini M. , et al.

Abstract: Metabotropic glutamate receptor 2 (mGluR2) is a therapeutic target for several neuropsychiatric disorders. An mGluR2 function in etiology could be unveiled by positron emission tomography (PET). In this regard, 5-(2-fluoro-4-[11C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide ([11C]13, [11C]mG2N001), a potent negative allosteric modulator (NAM), was developed to support this endeavor. [11C]13 was synthesized via the O-[11C]methylation of phenol 24 with a high molar activity of 212 ± 76 GBq/μmol (n = 5) and excellent radiochemical purity (>99%). PET imaging of [11C]13 in rats demonstrated its superior brain heterogeneity and reduced accumulation with pretreatment of mGluR2 NAMs, VU6001966 (9) and MNI-137 (26), the extent of which revealed a time-dependent drug effect of the blocking agents. In a nonhuman primate, [11C]13 selectively accumulated in mGluR2-rich regions and resulted in high-contrast brain images. Therefore, [11C]13 is a potential candidate for translational PET imaging of the mGluR2 function.

Hegde, Pooja V. ; Aragaw, Wassihun W. ; Cole, Malcolm S. ; Jachak, Gorakhnath ; Ragunathan, Priya ; Sharma, Sachin , et al.

Abstract: Tuberculosis (TB) remains a leading cause of infectious disease-related mortality and morbidity. Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mycobacterium tuberculosis (Mtb), but its mechanism of action has remained enigmatic. PZA is a prodrug converted by pyrazinamidase encoded by pncA within Mtb to the active moiety, pyrazinoic acid (POA) and PZA resistance is caused by loss-of-function mutations to pyrazinamidase. We have recently shown that POA induces targeted protein degradation of the enzyme PanD, a crucial component of the CoA biosynthetic pathway essential in Mtb. Based on the newly identified mechanism of action of POA, along with the crystal structure of PanD bound to POA, we designed several POA analogs using structure for interpretation to improve potency and overcome PZA resistance. We prepared and tested ring and carboxylic acid bioisosteres as well as 3, 5, 6 substitutions on the ring to study the structure activity relationships of the POA scaffold. All the analogs were evaluated for their whole cell antimycobacterial activity, and a few representative mols. were evaluated for their binding affinity, towards PanD, through isothermal titration calorimetry. We report that analogs with ring and carboxylic acid bioisosteres did not significantly enhance the antimicrobial activity, whereas the alkylamino-group substitutions at the 3 and 5 position of POA were found to be up to 5 to 10-fold more potent than POA. Further development and mechanistic anal. of these analogs may lead to a next generation POA analog for treating TB.

Keywords: Tuberculosis ; Pyrazinoic acid ; pyrazinamide

Alternative Products

Product Details of [ 17933-03-8 ]

CAS No. :17933-03-8
Formula : C7H9BO2
M.W : 135.96
SMILES Code : CC1=CC(B(O)O)=CC=C1
MDL No. :MFCD00040198
InChI Key :BJQCPCFFYBKRLM-UHFFFAOYSA-N
Pubchem ID :2733950

Safety of [ 17933-03-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501

Computational Chemistry of [ 17933-03-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.14
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 41.23
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

40.46 ?2

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.19
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.33
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.61
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.3
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.24

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.81
Solubility 2.1 mg/ml ; 0.0155 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.64
Solubility 3.15 mg/ml ; 0.0231 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.64
Solubility 3.09 mg/ml ; 0.0227 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

 High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

 No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

 No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

 Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

 No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

 No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

 No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

 Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.28 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

 0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

 None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

 0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

 0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

 1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

 No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

 1.37

Application In Synthesis of [ 17933-03-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 17933-03-8 ]

[ 17933-03-8 ] Synthesis Path-Downstream   1~19

  • 1
  • [ 17933-03-8 ]
  • [ 51323-43-4 ]
YieldReaction ConditionsOperation in experiment
Add 200ml of dry CCl4, 9g of 3-methylphenylboronic acid to the three-necked flask,1.6g of benzoyl peroxide, heated to 65 C with stirring under nitrogen protection, constant temperature for 5min,Initiate benzoyl peroxide. 11.64 g of N-bromosuccinimide were added in portions,After refluxing overnight, the temperature was lowered to room temperature, stirred for a while, and then filtered, and the product was washed with a mixed solvent of petroleum ether: ethyl acetate = 8: 1,13.5 g of 3-bromomethylphenylboronic acid was obtained in a yield of 95.32% and a purity of 91.33%.
  • 2
  • [ 10386-27-3 ]
  • [ 17933-03-8 ]
  • [ 158503-49-2 ]
  • 3
  • [ 128-08-5 ]
  • [ 17933-03-8 ]
  • [ 51323-43-4 ]
  • 5
  • [ 3621-82-7 ]
  • [ 17933-03-8 ]
  • [ 1315571-12-0 ]
YieldReaction ConditionsOperation in experiment
87% With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In 1,4-dioxane; water; at 80℃; for 6h;Inert atmosphere; General procedure: A 1,4-dioxane solution (3?mL) of 1, arylboronic acid (1.2?equiv), aqueous K2CO3 (2.0?M, 1.0?mL) and Pd(PPh3)4 (3?mol?percent) was heated at 80?°C for 6?h under argon atmosphere. After cooling to 20?°C, H2O was added and the reaction mixture was extracted with CH2Cl2 (3×25?mL). The organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (silica gel, heptane/EtOAc).#10;
  • 6
  • [ 4265-25-2 ]
  • [ 17933-03-8 ]
  • [ 64-19-7 ]
  • 2-methyl-(m-tolyl)-2,3-dihydrobenzofuran-3-yl acetate [ No CAS ]
  • 2-methyl-(m-tolyl)-2,3-dihydrobenzofuran-3-yl acetate [ No CAS ]
  • 7
  • [ 10323-39-4 ]
  • [ 17933-03-8 ]
  • [ 887340-16-1 ]
  • 8
  • [ 17933-03-8 ]
  • [ 4467-07-6 ]
  • 9
  • [ 221044-05-9 ]
  • [ 17933-03-8 ]
  • [ 1608124-59-9 ]
YieldReaction ConditionsOperation in experiment
99% With dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer; silver trifluoroacetate; In methanol; at 60℃;Schlenk technique; Inert atmosphere; General procedure: A mixture of N-pyrimidyl indoles 1 (0.20 mmol, 1.0 equiv.), arylboronicacids 2 (0.40 mmol, 2.0 equiv.),AgOOCF3 (0.80 mmol, 4.0 equiv.), and [RhCp*Cl2]2(0.002 mmol, 0.01 equiv.) were combined in MeOH (1.0 mL) in a dried Schlenk tubeunder a argon atmosphere. The resulting mixture was stirred at 60 C andmonitored by TLC. Uponcompletion or no further improvement of reaction, the reaction mixture wascooled to room temperature and added with Et3N (1 mL). Then themixture was filtered through a pad of silica gel eluting with 25 mL of CH2Cl2.The solvent was removed under reduced pressure and the residue was purified byflash chromatography on silica gel to afford the desired products.
  • 10
  • potassium phosphate [ No CAS ]
  • [ 17933-03-8 ]
  • [ 16657-07-1 ]
  • [ 603-35-0 ]
  • 4-(3-methylphenyl)indene [ No CAS ]
YieldReaction ConditionsOperation in experiment
100% With dichlorobis(triphenylphosphine)palladium[II]; In 1,2-dimethoxyethane; (1) Synthesis of 4-(3-methylphenyl)indene 38 g (180 mmol) of tripotassium phosphate, 100 mL of distilled water, 100 mL of DME, 10 g (73.6 mmol) of 3-methylphenylboronic acid, 12.0 g (61.5 mmol) of <strong>[16657-07-1]7-bromo-1H-indene</strong>, 323 mg (0.460 mmol) of dichlorobis(triphenylphosphine)palladium, and 432 mg (1.65 mmol) of triphenyl phosphine were put into a 500-mL glass reactor in that order, and then heated under reflux at 90 C. for 8 hours. This was left cooled to room temperature, then the reaction liquid was poured into 100 mL of distilled water, transferred into a separatory funnel, and extracted three times with hexane. At room temperature 6 mL of concentrated hydrochloric acid was added to the hexane solution, then stirred at room temperature for 30 minutes, the palladium compound was precipitated, filtered out through filter paper, and the filtrate was washed three times each with saturated saline water and distilled water, and dried with sodium sulfate. Sodium sulfate was filtered away, the solvent was evaporated away under reduced pressure, and the residue was purified through silica gel column chromatography (developing solvent, hexane/diisopropyl ether=20/1) to give 12.7 g (yield 100%) of 4-(3-methylphenyl)indene as a colorless oil.
  • 11
  • [ 17933-03-8 ]
  • [ 16657-07-1 ]
  • 2,2-bis(4-(3-methylphenyl)-inden-1-yl)propane [ No CAS ]
  • 12
  • [ 13304-62-6 ]
  • [ 17933-03-8 ]
  • C17H18FNO [ No CAS ]
  • C17H18FNO [ No CAS ]
  • 13
  • [ 17933-03-8 ]
  • [ 16657-07-1 ]
  • 4-(3-methylphenyl)indene [ No CAS ]
YieldReaction ConditionsOperation in experiment
100% With bis-triphenylphosphine-palladium(II) chloride; potassium phosphate; triphenylphosphine; In 1,2-dimethoxyethane; water; at 90℃; for 8h; 38 g (180 mmol) of tripotassium phosphate, 100 mL of distilled water, 100 mL of DME, 10 g (73.6 mmol) of 3-methylphenylboronic acid, 12.0 g (61.5 mmol) of <strong>[16657-07-1]7-bromo-1H-indene</strong>, 323 mg (0.460 mmol) of dichlorobis(triphenylphosphine)palladium, and 432 mg (1.65 mmol) of triphenyl phosphine were put into a 500-mL glass reactor in that order, and then heated under reflux at 90 C. for 8 hours. This was left cooled to room temperature, then the reaction liquid was poured into 100 mL of distilled water, transferred into a separatory funnel, and extracted three times with hexane. At room temperature 6 mL of concentrated hydrochloric acid was added to the hexane solution, then stirred at room temperature for 30 minutes, the palladium compound was precipitated, filtered out through filter paper, and the filtrate was washed three times each with saturated saline water and distilled water, and dried with sodium sulfate. Sodium sulfate was filtered away, the solvent was evaporated away under reduced pressure, and the residue was purified through silica gel column chromatography (developing solvent, hexane/diisopropyl ether=20/1) to give 12.7 g (yield 100%) of 4-(3-methylphenyl)indene as a colorless oil.
  • 14
  • [ 52133-67-2 ]
  • [ 17933-03-8 ]
  • ethyl 2-(m-tolyl)-1H-pyrrole-3-carboxylate [ No CAS ]
  • 15
  • [ 2905-65-9 ]
  • [ 17933-03-8 ]
  • [ 128460-74-2 ]
YieldReaction ConditionsOperation in experiment
94% With potassium phosphate; 3-(dicyclohexylphosphino)-2-(2,6-dimethoxyphenyl)-1-methyl-1H-indole; palladium diacetate; palladium; In 1,4-dioxane; at 100℃; for 2h;Schlenk technique; Inert atmosphere; General procedure: Palladium acetate (0.0022 g, 0.01 mmol), a phosphine ligand (palladium: phosphine ligand ratio of 1.0 mol%: 4 mol%) and A teflon-coated magnetic stir bar was placed in a 20 mL Schlenk tube, the system replaced with nitrogen, then 10 mL of freshly distilled dioxane was added and they were stirred for 10 minutes to form the palladium complex. Meanwhile, a chloro-aromatic hydrocarbon (1.0 mmol), substituted phenylboronic acid (1.5 mmol), potassium phosphate (3.0 mmol) and a Teflon-coated magnetic stir bar were placed in another 20 mL Schlenk tube. After 3 cycles of vacuum nitrogen back and forth, the appropriate amount (eg, 0.1 mL, 0.01 mol%) of the stock palladium complex solution was withdrawn by means of a gas-tight syringe to a column containing the chloroarene (1.0 mmol), substituted phenylboronic acid 1.5 mmol), potassium phosphate (3.0 mmol) and a teflon-coated magnetic stir bar and a nitrogen-protected Schlenk tube. Finally, a corresponding amount of freshly distilled dioxane was added (final amount of solvent was 3.0 mL). The Schlenk tube was then placed in an oil bath preheated to 100 C for 2-24 hours, as shown in the reaction scheme below. After the reaction was completed, the reaction tube was cooled to room temperature, the reaction was stopped, ethyl acetate (6.0 mL) and water (2.0 mL) were added to the system, and the organic layer was subjected to gas chromatographic analysis. Thereafter, the mixture is further extracted with about 10 mL of ethyl acetate in three to four times, and then the organic phases are combined. After the organic phase is concentrated under reduced pressure, the concentrate is purified by silica gel column chromatography to obtain a cross-coupled product.
  • 16
  • [ 17933-03-8 ]
  • [ 5350-41-4 ]
  • [ 620-47-3 ]
  • 17
  • [ 1001070-33-2 ]
  • [ 17933-03-8 ]
  • 1-(phenylsulfonyl)-5-(m-tolyl)-1H-pyrrolo[2,3-b]pyridine [ No CAS ]
  • 18
  • [ 31161-46-3 ]
  • [ 17933-03-8 ]
  • C18H14OS [ No CAS ]
  • 19
  • [ 17933-03-8 ]
  • [ 39549-79-6 ]
  • 7-methyl-2-(m-tolyl)-2,3-dihydrobenzo[d][1,3,2]diazaborinin-4(1H)-one [ No CAS ]
 

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 17933-03-8 ]

Organoborons

Chemical Structure| 172975-69-8

A119477 [172975-69-8]

3,5-Dimethylphenylboronic acid

Similarity: 0.97

Chemical Structure| 55499-44-0

A165802 [55499-44-0]

2,4-Dimethylphenylboronic acid

Similarity: 0.97

Chemical Structure| 2156-04-9

A173790 [2156-04-9]

4-Vinylbenzeneboronic acid

Similarity: 0.97

Chemical Structure| 16419-60-6

A203980 [16419-60-6]

2-Methylphenylboronic acid

Similarity: 0.97

Chemical Structure| 55499-43-9

A204724 [55499-43-9]

3,4-Dimethylphenylboronic acid

Similarity: 0.97

Aryls

Chemical Structure| 172975-69-8

A119477 [172975-69-8]

3,5-Dimethylphenylboronic acid

Similarity: 0.97

Chemical Structure| 55499-44-0

A165802 [55499-44-0]

2,4-Dimethylphenylboronic acid

Similarity: 0.97

Chemical Structure| 2156-04-9

A173790 [2156-04-9]

4-Vinylbenzeneboronic acid

Similarity: 0.97

Chemical Structure| 16419-60-6

A203980 [16419-60-6]

2-Methylphenylboronic acid

Similarity: 0.97

Chemical Structure| 55499-43-9

A204724 [55499-43-9]

3,4-Dimethylphenylboronic acid

Similarity: 0.97